Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

May 31, 2006

Study Completion Date

January 31, 2007

Conditions
Arterial Occlusive DiseasePeripheral Vascular DiseaseIschemia
Interventions
GENETIC

HGF plasmid

Intramuscular injections into index leg on Days 0, 14, and 28

Trial Locations (24)

10003

Diabetes Foot and Ankle Center, New York

10021

NYPH-NY Weill Cornell Medical Center, New York

14642

University of Rochester, Rochester

20422

VA Medical Center Surgical Service (112), Washington D.C.

27834

Pitt County Memorial Hospital, Greenville

30342

American Cardiovascular Research Institute, Atlanta

32501

Basptist Hospital, Pensacola

33606

University of South Florida College of Medicine, Tampa

35211

Cardiology, P.C., Birmingham

43606

Jobst Vascular Center, Toledo

43614

Medical College of Ohio, Toledo

44195

The Cleveland Clinic Foundation, Cleveland

45219

The Lindner Clinical Trial Center, Cincinnati

46290

The Care Group, LLC, Indianapolis

55407

Minneapolis Heart Institute Foundation, Minneapolis

60637

University of Chicago Hospitals, Chicago

70002

The Ochsner Heart and Vascular Institute, Metairie

72205

Central Arkansas Veteran's Healthcare System, Little Rock

73104

University of Oklahoma Health Sciences Center, Oklahoma City

77030

Baylor College of Medicine, Houston

78215

Peripheral Vascular Associates, San Antonio

90048

Cedars-Sinai Medical Center, Los Angeles

94305

Falk Cardiovascular Research Center, Stanford

03756

Dartmouth - Hitchcock Medical Center, Lebanon

All Listed Sponsors
lead

AnGes USA, Inc.

INDUSTRY

NCT00060892 - Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia | Biotech Hunter | Biotech Hunter